This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Merck & Co., Inc.
Drug Names(s): Desloratadine, Aerius, Neoclarityn, Azomyr, Aerinaze (desloratadine/pseudoephedrine), MK-4117
Description: Clarinex (Desloratadine) is the second generation of Claritin (Loratadine). Desloratadine is the most active metabolite of loratadine; indeed, it is 14-17 times more potent than its predecessor.
Clarinex (desloratadine) is a long-acting tricyclic anti-histamine with selective H-1 receptor (H1R) histamine antagonist activity. Histamine, acting on H1-receptors, produces pruritis, vasodilatation, hypotension, flushing, headache, tachycardia, bronchoconstriction, increases vascular permeability, potentiates pain, and more.
Deal Structure: Desloratadine was originally developed by Sepracor.
Schering-Plough and Sepracor
In December 1997, Schering-Plough and Sepracor announced a licensing agreement giving Schering-Plough exclusive worldwide rights to Sepracor's patents relating to desloratadine. Sepracor will receive royalties upon launch of CLARINEX in the U.S.
Merck and Schering-Plough
In March 2009, Merck & Co and Schering-Plough announced that their Boards of Directors have unanimously approved a definitive merger agreement under which Merck and Schering-Plough will combine, under the name Merck, in a stock and cash transaction. Under the terms of the agreement, Schering-Plough shareholders will receive 0.5767 shares and $10.50 in cash for each share of Schering-Plough. Each Merck share will automatically become a share of the combined company.
Dainippon Sumitomo Pharma and Sepracor
In September 2009, Dainippon Sumitomo Pharma (DSP) and Sepracor announced that they entered into...See full deal structure in Biomedtracker
Partners: Sumitomo Dainippon Pharma Co., Ltd. Kyorin Pharmaceutical Co., Ltd. DRI Capital Inc.
Pink Sheet Clarinex FDA Reviewers
Pink Sheet Clarinex Clinical Development
Pink Sheet Clarinex Clinical Protocols
Pink Sheet Clarinex exclusivity
Additional information available to subscribers only: